-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*For medical professionals only
What are the diagnostic criteria for Alzheimer's disease?Xu Jun
Chief physician, professor, doctoral supervisor, leader of Beijing Youth Top-notch Team, academic leader of cognitive impairment at Beijing Tiantan Hospital Neurology Center affiliated to Capital Medical University
Zhao Qianhua
Associate Professor of Neurology, Huashan Hospital, Fudan University, Master Supervisor, National Clinical Research Center for Geriatric Diseases (Huashan) PI
References:
[1] McKhann G,Drachman D,Folstein M,et al.
Clinical diagnosis of Alzheimer's disease:Report of the NINCDS‐ADRDA Work Group*under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease[J].
Neurology,1984,34(7):939-939.
[2] Dubois B,Feldman H H,Jacova C,et al.
Research criteria for the diagnosis of Alzheimer's disease:revising the NINCDS–ADRDA criteria[J].
The Lancet Neurology,2007,6(8):734-746.
[3] Dubois B,Feldman H H,Jacova C,et al.
Revising the definition of Alzheimer's disease:a new lexicon[J].
The Lancet Neurology,2010,9(11):1118-1127.
[4] Dubois B,Feldman H H,Jacova C,et al.
Advancing research diagnostic criteria for Alzheimer's disease:the IWG-2 criteria[J].
The Lancet Neurology,2014,13(6):614-629.
[5] Sperling R A,Aisen P S,Beckett L A,et al.
Toward defining the preclinical stages of Alzheimer’s disease:Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease[J].
Alzheimer's&dementia,2011,7(3):280-292.
[6] Jack Jr C R,Bennett D A,Blennow K,et al.
NIA-AA research framework:toward a biological definition of Alzheimer's disease[J].
Alzheimer's&Dementia,2018,14(4):535-562.
[7] Jack C R,Wiste H J,Therneau T M,et al.
Associations of amyloid,tau,and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia[J].
Jama,2019,321(23):2316-2325.
[8] Brookmeyer R,Abdalla N.
Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease[J].
Alzheimer's&Dementia,2018,14(8):981-988.
[9] Jack Jr C R,Therneau T M,Lundt E S,et al.
Long-term associations between amyloid positron emission tomography,sex,apolipoprotein E and incident dementia and mortality among individuals without dementia:hazard ratios and absolute risk[J].
Brain communications,2022,4(2):fcac017.
[10] Dubois B,Villain N,Frisoni G B,et al.
Clinical diagnosis of Alzheimer's disease:recommendations of the International Working Group[J].
The Lancet Neurology,2021,20(6):484-496.
Come to the "Doctor's Station" and take a look 👇
Source of this articleMedical Neurology ChannelThis article is compiled | The medical community reviewed this article | Jun Xu, Beijing Tiantan Hospital, Capital Medical University; Qianhua Zhao is the responsible editor of Huashan Hospital affiliated to Fudan University
Copyright statement
This article is original, please contact authorization-End-
Past "Experts Take You to AAIC" wonderful articles
1.
Is there a causal relationship between dementia and cerebrovascular disease? This study takes you to find out
2.
A new generation of AD treatments is coming, come in and gain insights
org.
cn*The medical community strives to be accurate and reliable in the review of published content, but does not make any commitment and guarantee as to the timeliness of published content, as well as the accuracy and completeness of the cited materials (if any), nor assumes any liability
arising from the outdated content or the possible inaccuracy or incompleteness of the cited materials.
Relevant parties are invited to verify separately when adopting or using this as a basis for decision-making
.